ArticleMedicine2025
Reticulated acanthoma with sebaceous differentiation: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deeply Pigmented Reticulated Acanthoma with Sebaceous Differentiation Mimicking Cutaneous Malignancy: A Case Report and Review of the Literature.Dermatopathology (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
rationaleReticulated acanthoma with sebaceous differentiation (RASD) is a rare and benign cutaneous neoplasm that is characterized by reticulated epidermal hyperplasia and differentiation of mature sebaceous cells. Due to the scarcity of this condition, the potential association with Muir-Torre syndrome (MTS) remains the subject of debate. PATIENT CONCERNS: A 52-year-old Chinese woman presented with a 3-year history of a solitary papule on the right buttock. DIAGNOSES: Histopathology provided a confirmed diagnosis of RASD. Immunohistochemical analysis demonstrated uniform nuclear positivity for DNA mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2). The absence of visceral malignancies and a negative family history, combined with the immunohistochemical results, provided no evidence for an association with MTS.
interventionsThe lesion was completely excised with negative margins. OUTCOMES: No tumor recurrence was observed during 20 months of follow-up. LESSONS: This rare case highlights the critical role of histopathological examination. Given the limited body of documented evidence for an association between RASD and MTS, documented, albeit limited, baseline immunohistochemistry and colonoscopy should always be considered to rule out MTS in patients diagnosed with RASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.